scispace - formally typeset
F

Frederick M. Kahan

Researcher at Merck & Co.

Publications -  25
Citations -  4062

Frederick M. Kahan is an academic researcher from Merck & Co.. The author has contributed to research in topics: Thienamycin & Imipenem. The author has an hindex of 16, co-authored 25 publications receiving 3899 citations.

Papers
More filters
Journal ArticleDOI

The mechanism of action of fosfomycin (phosphonomycin)

TL;DR: The role of two stereospecific nutrient transport systems that by mediating the entry and accumulation of fosfomycin comprise the determining factors in the sensitivity of various bacteria to this polar antibiotic.
Journal ArticleDOI

Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces

TL;DR: Phosphonomycin is a newly discovered antibiotic produced by streptomycetes that is effective, when administered by the oral route, to mice infected with Gram-positive or Gram-negative microorganisms.
Journal ArticleDOI

Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

TL;DR: A new beta-lactam antibiotic, named thienamycin, was discovered in culture broths of Streptomyces MA4297, and subsequently determined to be a hitherto unrecognized species, is designated StrePTomyces cattleya (NRRL 8057).
Journal ArticleDOI

Antibacterial agents that inhibit lipid A biosynthesis

TL;DR: Synthetic antibacterials were identified that inhibit the second enzyme (a unique deacetylase) of lipid A biosynthesis that constitutes the outer monolayer of the outer membrane of Gram-negative bacteria and is essential for bacterial growth.
Journal ArticleDOI

Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I

TL;DR: The reduction in clearance of THM and MK0787 from plasma of rats and rabbits after ligation of renal arteries indicate that the kidneys are responsible for 35 and 92%, respectively, of metabolic drug clearance, and despite this unusual degree of metabolism localized in the kidney, the plasma half-life of MK 0787 and its efficacy against experimental systemic infections in animals remain satisfactory.